Search Page

The search found 4 results in 0.049 seconds.

Search results

  1. Biological DMARDs

    Biological DMARDs take the form of monoclonal antibodies (mAbs) and recombinant fusion proteins which modulate cytokine levels via mechanisms which inhibit T and B cell activation, or by directly inhibiting pro-inflammatory tumour necrosis factor alpha (TNFα). All cytokine modulators must be used under specialist supervision.

    Examples currently employed for anti-rheumatic therapy include:

    efaccena - 25/07/2016 - 2:22pm

  2. TNF binding proteins (under construction)

    TNF-α binding proteins can be monoclonal antibody in nature or can be recombinant proteins which act as circulating TNF-α receptors. To date their immunosuppressive activity is utilised in the treatment of autoimmune conditions.

    Anti-TNF-α monoclonal antibodies

    efaccena - 12/09/2016 - 11:09am

  3. Psoriasis

    Therapeutics for the management of psoriasis include both pharmacological (topical corticosteroids and non-corticosteroids, emollients, systemic therapies, biologic therapy) and non-pharmacological interventions (e.g. phototherapy).

    efaccena - 06/07/2017 - 2:35pm

  4. Disease-modifying anti-rheumatic drugs (DMARDs)

    Different types of arthritis (rheumatic disease) are treated with different drugs. The aim of the clinician is to prescribe drugs which improve symptoms and, where possible, slow or halt progress of the condition. As their name suggests, disease-modifying anti-rheumatic drugs (DMARDs) offer benefit via the latter mechanism. Full therapeutic response to DMARDs may take several months to become evident. Early intervention with DMARD therapy is recommended to control the signs and symptoms of rheumatic disease and to limit joint damage.

    efaccena - 22/07/2016 - 2:10pm